Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals Plc on February 28, 2012. The filing addresses a change in the registrant's certifying accountant following the completion of a merger transaction on January 18, 2012, between Azur Pharma Public Limited Company and Jazz Pharmaceuticals, Inc. The merger was treated as a reverse acquisition, with Jazz Pharmaceuticals, Inc. designated as the accounting acquirer.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and accounting firm transitions.
Material Changes
- Accountant Dismissal: The Audit Committee dismissed Ernst & Young LLP as the independent registered public accountants for Jazz Pharmaceuticals, Inc. effective February 28, 2012, following the delivery of the audit report for the year ended December 31, 2011.
- Accountant Engagement: KPMG (Dublin office) was engaged as the independent registered public accountants for the Company for the fiscal year ending December 31, 2012, effective upon the completion of the Merger.
- Historical Audits: Ernst & Young LLP audited the financial statements for the fiscal years ended December 31, 2010, and 2011. No adverse opinions, disclaimers, or qualifications were issued during this period.
Outlook, Risks, and Contingencies
The filing confirms that there were no disagreements with Ernst & Young LLP regarding accounting principles, practices, financial statement disclosures, or auditing scope/procedures during the fiscal years 2010 and 2011, or the interim period through February 28, 2012. Additionally, no reportable events under Item 304(a)(1)(v) of Regulation S-K occurred. The company has provided the required disclosures to Ernst & Young LLP, and a letter from the firm agreeing with these disclosures is filed as Exhibit 16.1.
Key Facts for Investor Verification
- Verify the effective date of the KPMG engagement for the 2012 fiscal year audit.
- Confirm the absence of any undisclosed disagreements with the former auditor, Ernst & Young LLP, regarding the 2010 and 2011 financial statements.
- Review the January 18, 2012 Form 8-K for detailed information regarding the Merger and the initial engagement of KPMG.
- Examine Exhibit 16.1 for the formal letter from Ernst & Young LLP confirming their agreement with the company's disclosures.